All In Biotech

Drug Trial Radar · NCT07142291

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Mar 2027

Study completion Jun 2027

Sponsor

Lead sponsor
PhenoNet, Inc.Industry
Sponsor type
Industry
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • Cromolyn Sodium (34.2 mg BID)Drug

    17.1 mg, BID, oral inhalation

  • Cromolyn Sodium (17.1 mg BID)Drug

    34.2 mg, BID, oral inhalation via dry powder inhaler

  • PlaceboDrug

    Placebo comparator matched to active treatment.

  • Riluzole (100 mg)Drug

    50 mg, oral tablet, BID, standard of care treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change in ALSFRS-R total score from baseline to Week 24Time frame: Baseline to Week 24
  2. Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Baseline to Week 24

Locations

22 sites in 6 countries. Site status is shown where the registry gives one.

  • Honor Health Neurology - Bob Bove Neuroscience Institute

    Scottsdale, Arizona · Recruiting

  • University of California San Diego

    La Jolla, California · Recruiting

  • Sutter Health - California Pacific Medical Center Research Institute

    San Francisco, California · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Lange Neurology

    New York, New York · Recruiting

  • NEUROHK s.r.o.

    Hradec Králové, Czechia · Recruiting

  • Fakultni Nemocnice Hradec Kralove

    Hradec Králové, Czechia · Recruiting

  • Thomayer University Hospital - Fakultni Thomayerova nemocnice

    Prague, Czechia · Recruiting

  • Charité Centrum für Neurologie, Neurochirurgie und Psychiatrie

    Berlin, Germany · Recruiting

  • DIAKOVERE Henriettenstift - Klinik für Neurologie und Klinische Neurophysiologie

    Hanover, Germany · Recruiting

  • Universitaetsklinikum Schleswig-Holstein

    Lübeck, Germany · Recruiting

  • Michalski i Partnerzy Lekarze Spółka Partnerska

    Krakow, Poland · Recruiting

  • SP ZOZ Szpital Uniwersytecki w Krakowie

    Krakow, Poland · Recruiting

  • Centrum Medyczne NeuroProtect (NeuroProtect Medical Center)

    Warsaw, Poland · Recruiting

  • City Clinic Research

    Warsaw, Poland · Recruiting

  • University Clinical Center of Serbia

    Belgrade, Serbia · Recruiting

  • Hospital General Universitario Dr. Balmis de Alicante

    Alicante, Spain · Recruiting

  • Barcelona Sea Hospital (Hospital Del Mar De Barcelona)

    Barcelona, Spain · Recruiting

  • Hospital Universitario Vall D Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramon Y Cajal

    Madrid, Spain · Recruiting

  • Hospital Regional Universitario De Malaga

    Málaga, Spain · Recruiting

  • Hospital Universitario Virgen Del Rocio

    Seville, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.